

Sharon E. Kennedy

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE
FORM PTO-147

Digitally signed by
Sharon E. Kennedy
DN: cn=Sharon E.
Kennedy, c=US

Sheet 1 of 1

LIST OF ART CITED BY APPLICANT

ATTY. DOCKET	17-59 CON-2-CIP1-CIP1 (BOT)	SERIAL NO.: 10/752,871
APPLICANT	email=sharon.kennedy@uspto.gov	TITLE: INTRAVITREAL BOTULINUM TOXIN IMPLANT
FILING DATE	JANUARY 20 2006 17:20:06 -04'00'	GROUP: 1615

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)
	AA						
	AB						
	AC						
	AD						
	AE						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/no)
/SK/	BA	WO99/37326	29JUL1999	PCT	A61K	9/16	Y
	BB						
	BC						
	BD						
	BE						
	BF						

OTHER ART

(Including Author, Title, Date, Pertinent Pages, etc.)

/SK/	CA	JANKOVIC J et al., "Botulinum toxin treatment of tremors", <u>Neurology</u> , vol. 41, no. 8, August 1991, pp. 1185-1188
/SK/	CB	MAYSINGER D et al., "Preparation and in vivo effect of microencapsulated cholinotoxin", <u>International Journal of Pharmaceutics</u> , vol. 63, no. 2, 15 September 1990, pp. 149-154
/SK/	CC	MEN Y et al., "A single administration of tetanus toxoid in biodegradable microspheres elicits T cell and antibody responses similar or superior to those obtained with aluminum hydroxide", <u>Vaccine</u> , vol. 13, no. 7, 1995, pp. 683-689
	CD	
	CE	
	CF	


EXAMINER /Sharon Kennedy/

DATE CONSIDERED 05/10/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sharon E. Kennedy

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE
FORM PTOS-4



Sheet 1 of 6

LIST OF ART CITED BY APPLICANT

ATTY. DOCKET: 17359CON2CIP1CIP1 (BOT) Digitally signed by Sharon E. Kennedy	SERIAL NO.: 10/752,871
APPL. BY: Sharon E. Kennedy, Secretary, Donovan c=US, o=USPTO, ou=1615	TITLE: INTRAVITREAL BOTULINUM TOXIN IMPLANT
FILING DATE: January 6, 2004 email=sharon.kennedy@uspto.gov	GROUP: 1615

Date: 2007.05.10 17:18:22 -04'00'

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)
/SK/	AA	2003-0095995					
	AB	3,523,906					
	AC	3,691,090					
	AD	3,737,337					
	AE	3,773,919					
	AF	4,389,330					
	AG	4,767,628					
	AH	5,019,400					
	AI	5,437,291					
	AJ	5,501,856					
	AK	5,667,808					
	AL	5,670,484					
	AM	5,714,468					
	AN	5,766,605					
	AO	5,902,565					
	AP	5,980,945					
	AQ	5,980,948					
	AR	6,007,843					
	AS	6,011,011					
	AT	6,022,554					
	AU	6,063,768					
	AV	6,113,915					
	AW	6,139,845					
	AX	6,143,306					
	AY	6,265,379					
	AZ	6,299,893					
	AAA	6,306,403					
	ABB	6,306,423B1					
	ACC	6,312,708					
/SK/	ADD	6,328,977					

EXAMINER /Sharon Kennedy/

DATE CONSIDERED 05/10/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



ART CITED BY APPLICANT

ATTY. DOCKET: 17359CON2CIP1CIP1 (BOT)	SERIAL NO.: 10/752,871
APPLICANT: Stephen Donovan	TITLE: INTRAVITREAL BOTULINUM TOXIN IMPLANT
FILING DATE: January 6, 2004	GROUP: 1615

/SK/	AEE	6,358,513					
	AFF	6,365,164B1					
	AGG	6,383,509B1					
	AHH	6,395,277					
	All	6,423,319					
	AJJ	6,458,365					
	AKK	6,464,986					
	ALL	6,699,493					
/SK/	AMM	6,726,918					

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/no)
/SK/	BA	EP 654,256					
	BD						

OTHER ART

(Including Author, Title, Date, Pertinent Pages, etc.)

/SK/	CA	am Ende, M.T. et al., <i>Factors influencing drug and protein transport and release from ionic hydrogels</i> , Reactive Polymers, 25 (1995);127-137
/SK/	CB	Aoki K.R., Cui M, <i>Mechanisms of the Antinociceptive Effect of Subcutaneous BOTOX®: Inhibition of Peripheral and Central Nociceptive Processing</i> , Cephalalgia 23(7);649:2003
/SK/	CC	Aoki K.R., <i>Pharmacology and immunology of botulinum toxin serotypes</i> , J Neurol 248(suppl 1);I/3 -I/10:2001
/SK/	CD	Argoff, <i>A Focused Review on the Use of Botulinum Toxins for Neuropathic Pain</i> , Clin J Pain (2002) 18(6 Suppl);S177-S181
/SK/	CE	Bell, C. et al., <i>Poly(methacrylic Acid-g-Ethylene Glycol) Hydrogels as pH Responsive Biomedical Materials</i> , Mater Res Soc Symp Proc (1994), 331;199-204
/SK/	CF	Bigalke H., et al., <i>Botulinum A Neurotoxin Inhibits Non-Cholinergic Synaptic Transmission in Mouse Spinal Cord Neurons in Culture</i> , Brain Research 360 (1985);318-324

EXAMINER /Sharon Kennedy/

DATE CONSIDERED 05/10/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



LIST OF ART CITED BY APPLICANT

ATTY. DOCKET: 17359CON2CIP1CIP1 (BOT)	SERIAL NO.: 10/752,871
APPLICANT: Stephen Donovan	TITLE: INTRAVITREAL BOTULINUM TOXIN IMPLANT
FILING DATE: January 6, 2004	GROUP: 1615

/SK/	CG	Bigalke H., et al., <i>Tetanus Toxin and Botulinum A Toxin Inhibit Release and Uptake of Various Transmitters, as Studied with Particulate Preparations From Rat Brain and Spinal Cord</i> , Naunyn-Schmiedeberg's Arch Pharmacol 316 (1981);244-251
	CH	Binz T. et al., <i>The Complete Sequence of Botulinum Neurotoxin Type A and Comparison with Other Clostridial Neurotoxins</i> , J Biological Chemistry 265(16);9153-9158 (1990)
	CI	Brazel C. et al., <i>Temperature- and pH- Sensitive Hydrogels for Controlled Release of Antithrombotic Agents</i> , Mater Res Soc Symp Proc (1994), 331;211-216
	CJ	Bushara K., <i>Botulinum toxin and rhinorrhea</i> , Otolaryngology - Head Neck Surg 1996;114(3):507
	CK	Cardamone M., et al., <i>In Vitro Testing of a Pulsatile Delivery System and its In Vivo Application for Immunization Against Tetanus Toxoid</i> , J Controlled Release 47;205-219:1997
	CL	Cleland J.L., et al, <i>Development of a Single-Shot Subunit Vaccine for HIV-1: Part 4. Optimizing Microencapsulation and Pulsatile Release of MN rpg120 from Biodegradable Microspheres</i> , J Cont Rel 47;135-150:1997
	CM	Cleland, J. et al., <i>Development of a Single-shot Subunit Vaccine for HIV-1. 5. Programmable in Vivo Autoboot and Long Lasting Neutralizing Response</i> , J Pharm Sci (1998) 87:1; 1489-95
	CN	Cleland, Jeffrey L., <i>Solvent Evaporation Processes for the Production of Controlld Release Biodegradable Microsphere Formulations for Therapeutics and Vaccines</i> , Biotechnol Prog (1998), 14(1):102-7
	CO	Coffield J., et al., <i>Site and Action of Botulinum Neurotoxin</i> , Therapy With Botulinum Toxin, Ed. Jankovic J. et al., Publ. Marcel Dekker, Inc., (1994), page 5
	CP	Cui M, Aoki KR, <i>Botulinum toxin type A (BTX-A) reduces inflammatory pain in the rat formalin model</i> , Cephalalgia 20(4);414:2000
	CQ	Doelker E., <i>Cellulose Derivatives</i> , Adv Polym Sci 107; 199-265:1993
	CR	Dong, Liang-Chang et al., <i>A novel approach for preparation of pH-sensitive hydrogels for enteric drug delivery</i> , J. Contr Rel 15 (1991);141-152
	CS	Durham P., et al., <i>Mechanism of botulinum toxin type-A Inhibition of Calcitonin Gene-Related Peptide Secretion from Trigeminal Nerve Cells</i> , Cephalalgia (2003) 23(7);690
↓	CT	Garry, M. et al., <i>Evaluation of the efficacy of bioerodible bupivacaine polymer system on antinociception and inflammatory mediator release</i> , Pain 82 (1999);49-55
/SK/		

EXAMINER /Sharon Kennedy/

DATE CONSIDERED 05/10/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



LIST OF ART CITED BY APPLICANT

ATTY. DOCKET: 17359CON2CIP1CIP1 (BOT)	SERIAL NO.: 10/752,871
APPLICANT: Stephen Donovan	TITLE: INTRAVITREAL BOTULINUM TOXIN IMPLANT
FILING DATE: January 6, 2004	GROUP: 1615

/SK/	CU	Gonelle-Gispert et al., <i>SNAP-25a and -25b isoforms are both expressed in insulin-secreting cells and can function in insulin secretion</i> , Biochem J. 339 (1999) (pt 1):159-165
	CV	Habermann E. et al., <i>Tetanus Toxin and Botulinum A and C Neurotoxins Inhibit Noradrenaline Release From Cultured Mouse Brain</i> , J Neurochem (1988), 51(2):522-527
	CW	Habermann E., <i>Inhibition by Tetanus and Botulinum A Toxin of the release of [³H]Noradrenaline and [³H]GABA From Rat Brain Homogenate</i> , Experientia 44 (1988):224-226
	CX	Habermann, E., <i>I-Labeled Neurotoxin from Clostridium Botulinum A: Preparation, Binding to Synaptosomes and Ascent to the Spinal Cord</i> , Naunyn-Schmiedeberg's Arch. Pharmacol. 1974; 281, 47-56
	CY	Hanes, J. et al., <i>New Advances in Microsphere-Based Single-Dose Vaccines</i> , Adv Drug Del Rev 28 (1997):97-119
	CZ	Heller, <i>Biodegradable Polymers in Controlled Drug Delivery</i> , CRC Critical Reviews in Therapeutic Drug Carrier Systems, Vol. 1, Issue 1, Boca Raton, FL (1987); 39-90
	CAA	Johansen P. et al., <i>Improving Stability and Release Kinetics of Microencapsulated Tetanus Toxoid by Co-Encapsulation of Additives</i> , Pharm Res 15:7(1998):1103-1110
	CBB	Kissel et al., <i>Microencapsulation of Antigens Using Biodegradable Polymers: Facts and Fantasies</i> , Behring Inst. Mitt., 98 (1997):172-183
	CCC	Kost, J. et al., <i>Magnetically enhanced insulin release in diabetic rats</i> , J. Biomed Mater Res (1987), 21:1367-1373
	CDD	Langer, R. et al., <i>Polymers for Sustained Release of Proteins and Other Macromolecules</i> , Nature 263 (1976); 797-800
	CEE	Langer, R., <i>New Methods of Drug Delivery</i> , Science 249 (1990):1527-1533
	CFF	Lewis D. H., <i>Controlled Release of Bioagents from Lactide/Glycolide Polymers</i> , Biodegradable Polymers as Drug-Delivery Systems, Ed. Chasin M., et al., Marcel Dekker, New York (1990), pages 1-41
	CGG	Mallapragada S.K. et al., <i>Drug Delivery Systems</i> , chapter 27, Ed. Von Recum, A. F. <i>Handbook of Biomaterials Evaluation</i> , second edition, Publ. Taylor & Francis (1999), 431-433
↓ /SK/	CHH	Marchese Ragona, R. et al., <i>Management of Parotid Sialoceles With Botulinum Toxin</i> , The Laryngoscope 109 (August 1999):1344-1346

EXAMINER /Sharon Kennedy/

DATE CONSIDERED 05/10/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



LIST OF ART CITED BY APPLICANT

ATTY. DOCKET: 17359CON2CIP1CIP1 (BOT)	SERIAL NO.: 10/752,871
APPLICANT: Stephen Donovan	TITLE: INTRAVITREAL BOTULINUM TOXIN IMPLANT
FILING DATE: January 6, 2004	GROUP: 1615

ISK/	CII	Men Y. et al., <i>A Single Administration of Tetanus Toxoid in Biodegradable Microspheres Elicits T Cell and Antibody Responses Similar or Superior to Those Obtained with Aluminum Hydroxide</i> , Vaccine (1995) 13, 683-689
	CJJ	Movement Disorders, Vol. 10, No. 3 (1995), pg. 376
	CKK	Moyer E. et al., <i>Botulinum Toxin Type B: Experimental and Clinical Experience of "Therapy With Botulinum Toxin"</i> , edited by Jankovic, J. et al. (1994), Marcel Dekker, Inc., Chapter 6, pages 71-85
	CLL	Naumann, M. et al., <i>Botulinum toxin type A in the treatment of focal, axillary and palmar hyperhidrosis and other hyperhidrotic conditions</i> , European J. Neurology (1999), 6 (Supp 4): S111-S115
	CMM	Pearce, L.B., <i>Pharmacologic Characterization of Botulinum Toxin For Basic Science and Medicine</i> , Toxicon 1997; 35(9):1373-1412 at 1393
	CNN	Powell, E. et al., <i>Controlled Release of Nerve Growth Factor from a Polymeric Implant</i> , Brain Res 1990;515(1-2):309-11
	COO	Rao, Jyoti et al., <i>Implantable Controlled Delivery Systems for Proteins Based on Collagen - pHEMA Hydrogels</i> , Biomaterials 1994;15(5):383-9
	CPP	Sanchez-Prieto, J. et al., <i>Botulinum Toxin A Blocks Glutamate Exocytosis From Guinea Pig Cerebral Cortical Synaptosomes</i> , Eur J. Biochem (1987) 165(3):675-681
	CQQ	Schantz, E.J., et al, <i>Properties and use of Botulinum toxin and Other Microbial Neurotoxins in Medicine</i> , Microbiological Reviews (1992), 56(1):80-99
	CRR	Schwendeman, S. et al., <i>Peptide, Protein, and Vaccine Delivery from Implantable Polymeric Systems-Progress and Challenges</i> , from Controlled Drug Delivery Challenges and Strategies, American Chemical Society (1997), Ed. Park K., chapter 12 (pages 229-267)
	CSS	Silberstein S. et al., <i>Botulinum toxin type A: Myths, facts, and current research</i> , Headache 2003 Jul;43 Suppl 1 1(Suppl 1):S1
	CTT	Singh, <i>Critical Aspects of Bacterial Protein Toxins</i> , pages 63-84 (chapter 4) of Natural Toxins II, edited by B.R. Singh et al., Plenum Press, New York (1976)
↓	CUU	Sinha V. et al., <i>Bioabsorbable Polymers for Implantable Therapeutic Systems</i> , Drug Development and Industrial Pharmacy 24(12):1129-1138 (1998)
ISK/	CVV	Sloop, R. et al., <i>Reconstituted botulinum toxin type A does not lose potency in humans if it is refrozen or refrigerated before 2 weeks before use</i> , Neurology 48 (January 1997):249-53:1997

EXAMINER /Sharon Kennedy/ DATE CONSIDERED 05/10/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



LIST OF ART CITED BY APPLICANT

ATTY. DOCKET: 17359CON2CIP1CIP1 (BOT)	SERIAL NO.: 10/752,871
APPLICANT: Stephen Donovan	TITLE: INTRAVITREAL BOTULINUM TOXIN IMPLANT
FILING DATE: January 6, 2004	GROUP: 1615

/SK/	CWW	Tobio M., et al., <i>A Novel System Based on a Poloxamer/PLGA Blend as a Tetanus Toxoid Delivery Vehicle</i> , Pharm Res (1999) 16(5);682-688
/SK/	CXX	Tracy et al., <i>Factors affecting the degradation rate of poly(lactide-co-glycolide) microspheres in vivo and in vitro</i> , Biomaterials 20 (1999);1057-1062
/SK/	CYY	USP 24; NF 19 (2000), pp. 1941-1951
/SK/	CZZ	Veronese, F.M. et al., <i>Polyorganophosphazene microspheres for drug release: polymer synthesis, microsphere preparation, in vitro and in vivo naproxen release</i> , Journal of Controlled Release 52 (1998);227-237
/SK/	CAAA	Weigand et al, <i>I-Labelled Botulinum A Neurotoxin: Pharmacokinetics in Cats after Intramuscular Injection</i> , Naunyn-Schmiedeberg's Arch. Pharmacol. 1976; 292, 161-165

EXAMINER /Sharon Kennedy/

DATE CONSIDERED 05/10/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.